Development and Analysis of a Stool Bank for Cancer Patients

Launched by PERSEPHONE BIOSCIENCES · Feb 27, 2020

Keywords

ClinConnect Summary

**Summary of the Clinical Trial: Development and Analysis of a Stool Bank for Cancer Patients**

This clinical trial is looking to understand how the bacteria in our gut, known as gut microbiota, can affect the success of cancer treatments, especially those called checkpoint inhibitors. By collecting samples from cancer patients, researchers hope to learn more about which specific bacteria and their activities might help improve cancer treatment outcomes. Unlike animals, humans have unique gut bacteria, so studying human samples is crucial for finding effective therapies.

If you are an adult (18 years or older) currently receiving any type of cancer immunotherapy, you may be eligible to participate in this study. Participants will be asked to provide samples of blood, urine, and stool—totaling five of each over the course of a year. The study is non-interventional, meaning you will continue your regular treatment without any changes. However, individuals with certain conditions like HIV or hepatitis, those who are pregnant or nursing, or those unable to provide consent are not eligible. This trial is currently recruiting and aims to enroll around 100 participants across two locations. Your involvement could help pave the way for new treatments that improve cancer care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men or women who are ≥ 18 years old who are undergoing any type of cancer immunotherapy
• • Subjects who are able to provide written informed consent
• Exclusion Criteria:
• • Subjects with HIV, Hepatitis B, or Hepatitis C
• • Subjects without the mental capacity to complete either a written or online questionnaire, alone or with assistance, or make sound decisions
• • Women who are pregnant or who plan on becoming pregnant
• • Women who are nursing